Target intelligence / Profile preview

Bacterial toxins and gut irritants

Molecular classification
Bacterial protein toxins, Lipopolysaccharides, Secretagogues, Other
01

Overview

Bacterial toxins and gut irritants represent a diverse group of substances produced by pathogenic bacteria or encountered in the gastrointestinal lumen that disrupt normal intestinal homeostasis. These include exotoxins, such as those from Vibrio cholerae or Clostridioides difficile, and endotoxins like lipopolysaccharides, which trigger excessive fluid secretion and inflammation by activating intracellular signaling pathways like the cystic fibrosis transmembrane conductance regulator (CFTR) (PubMed: 9446464). Gut irritants also encompass endogenous factors like malabsorbed bile acids or exogenous dietary components that provoke similar secretory or inflammatory responses (StatPearls: NBK549910). In therapeutic contexts, these entities are targeted to manage conditions like infectious diarrhea, traveler's diarrhea, and irritable bowel syndrome. Treatment strategies involve luminal binders like cholestyramine that adsorb toxins, neutralizing monoclonal antibodies like bezlotoxumab, or agents like crofelemer that block the physiological consequences of toxin-induced signaling (NEJM: 28148186, PubMed: 23195660). Consequently, while this category is broad and represents a functional group rather than a single molecular entity, it remains a primary focus for developing anti-diarrheal and anti-infective therapies.

Other names
EnterotoxinsExotoxinsEndotoxinsLuminal irritantsPathogenic secretagoguesBacterial exotoxinsGastrointestinal irritants
02

Mechanism of action

Toxin neutralization via monoclonal antibodies, luminal adsorption and physical binding, and inhibition of downstream secretory signaling pathways such as the CFTR chloride channel.

03

Biological functions

PathogenesisIon transport regulationEpithelial barrier disruptionInduction of inflammationCell deathSignal transduction
04

Disease associations

InfectionInfectious diarrheaGastroenteritisPseudomembranous colitisIrritable bowel syndromeBile acid malabsorptionFood poisoning
05

Safety considerations

Interference with the absorption of co-administered medicationsConstipationElectrolyte imbalancePotential masking of underlying systemic infectionBismuth-related neurotoxicity (rare/high dose)
06

Interacting drugs

Bezlotoxumab

8 more in the full profile.

07

Biomarkers

Clostridioides difficile toxin A/B assayFecal calprotectinStool culture for enterotoxigenic bacteriaFecal occult blood

Beyond the preview

Go deeper on Bacterial toxins and gut irritants.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial toxins and gut irritants.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call